IN2012DN01292A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN01292A IN2012DN01292A IN1292DEN2012A IN2012DN01292A IN 2012DN01292 A IN2012DN01292 A IN 2012DN01292A IN 1292DEN2012 A IN1292DEN2012 A IN 1292DEN2012A IN 2012DN01292 A IN2012DN01292 A IN 2012DN01292A
- Authority
- IN
- India
- Prior art keywords
- therapy
- preparing
- processes
- compound
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23743509P | 2009-08-27 | 2009-08-27 | |
| PCT/EP2010/062420 WO2011023733A1 (en) | 2009-08-27 | 2010-08-25 | Anhydrate forms of a pyridine derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN01292A true IN2012DN01292A (OSRAM) | 2015-06-05 |
Family
ID=42790943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1292DEN2012 IN2012DN01292A (OSRAM) | 2009-08-27 | 2010-08-25 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8796269B2 (OSRAM) |
| EP (1) | EP2470545B1 (OSRAM) |
| JP (3) | JP2013503134A (OSRAM) |
| KR (1) | KR20120056258A (OSRAM) |
| CN (1) | CN102639536B (OSRAM) |
| AU (1) | AU2010288502B2 (OSRAM) |
| BR (1) | BR112012003435A2 (OSRAM) |
| CA (1) | CA2772168C (OSRAM) |
| DK (1) | DK2470545T3 (OSRAM) |
| EA (1) | EA021411B1 (OSRAM) |
| ES (1) | ES2440938T3 (OSRAM) |
| IL (1) | IL217922A (OSRAM) |
| IN (1) | IN2012DN01292A (OSRAM) |
| MX (1) | MX2012002369A (OSRAM) |
| PL (1) | PL2470545T3 (OSRAM) |
| SG (1) | SG178231A1 (OSRAM) |
| WO (1) | WO2011023733A1 (OSRAM) |
| ZA (1) | ZA201200812B (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102639536B (zh) * | 2009-08-27 | 2015-03-18 | 尼尔医疗有限公司 | 吡啶衍生物的无水晶型 |
| WO2015200594A2 (en) * | 2014-06-25 | 2015-12-30 | Emory University | Methods of managing conditioned fear with neurokinin receptor antagonists |
| BR112017024852B1 (pt) * | 2015-05-18 | 2023-10-31 | KaNDy Therapeutics Limited | Usos de um composto antagonista do receptor nk-1/nk-3 duplo e de uma composição farmacêutica compreendendo dito composto para o tratamento de sintomas vasomotores associados com menopausa |
| ES2901616T3 (es) * | 2016-12-15 | 2022-03-23 | Glaxosmithkline Ip Dev Ltd | Compuestos NRF2 |
| PL3765024T3 (pl) * | 2018-03-14 | 2024-08-05 | KaNDy Therapeutics Limited | <div>Nowa formulacja farmaceutyczna zawierająca podwójnych antagonistów receptora nk-1/nk-3</div> |
| WO2021030335A1 (en) * | 2019-08-12 | 2021-02-18 | Millendo Therapeutics, Inc. | A stereoisomerically pure nk-3 receptor antagonist and crystalline forms thereof |
| KR20220101090A (ko) | 2019-11-15 | 2022-07-19 | 칸디 테라퓨틱스 리미티드 | Nt-814의 핵심 중간체인 6-클로로-4-(4-플루오로-2-메틸페닐)피리딘-3-아민의 새로운 화학적 제조 방법 |
| EP4431512A1 (en) | 2023-03-16 | 2024-09-18 | Bayer Consumer Care AG | Novel dual nk-1/nk-3 receptor antagonists |
| WO2025242585A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant |
| WO2025242584A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | A stable soft gelatin capsule formulation for elinzanetant |
| WO2025242583A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | Novel formulation comprising elinzanetant in a solid dispersion |
| WO2025261856A1 (en) * | 2024-06-18 | 2025-12-26 | Bayer Consumer Care Ag | Improved process for producing an elinzanetant precursor |
| US12533358B1 (en) | 2025-05-14 | 2026-01-27 | Bayer Consumer Care Ag | Methods of treatment with elinzanetant |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2359235T3 (es) * | 1999-02-24 | 2011-05-19 | F. Hoffmann-La Roche Ag | Derivados de 4-fenilpiridina y su empleo como antagonistas del receptor nk-1. |
| GB0203022D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| CA2514037C (en) * | 2003-01-31 | 2012-03-13 | F. Hoffmann-La Roche Ag | Crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-n-[6-(1,1-dioxo-1.lambda.6-thiomorpholin-4-yl)-4(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-n-methyl-isobutyramide |
| JP4490421B2 (ja) * | 2003-07-03 | 2010-06-23 | エフ．ホフマン−ラ ロシュ アーゲー | 統合失調症を処置するデュアルｎｋ１／ｎｋ３アンタゴニスト |
| PL1928886T3 (pl) * | 2005-09-09 | 2011-09-30 | Nerre Therapeutics Ltd | Pochodne pirydyny i ich zastosowanie w leczeniu zaburzeń psychotycznych |
| US20100190797A1 (en) * | 2007-12-11 | 2010-07-29 | Cipla Ltd. | Crystalline polymophic forms of zopiclone, processes for their preparation and their pharmaceutical compositions |
| GB0814340D0 (en) * | 2008-08-05 | 2008-09-10 | Smithkline Beecham Corp | Anhydrous crystol form fo a pyridine derivative |
| CN102639536B (zh) * | 2009-08-27 | 2015-03-18 | 尼尔医疗有限公司 | 吡啶衍生物的无水晶型 |
| JP6342662B2 (ja) * | 2014-01-29 | 2018-06-13 | 京セラ株式会社 | ドリルおよびそれを用いた切削加工物の製造方法 |
-
2010
- 2010-08-25 CN CN201080037918.3A patent/CN102639536B/zh active Active
- 2010-08-25 KR KR1020127004865A patent/KR20120056258A/ko not_active Ceased
- 2010-08-25 BR BR112012003435A patent/BR112012003435A2/pt active IP Right Grant
- 2010-08-25 IN IN1292DEN2012 patent/IN2012DN01292A/en unknown
- 2010-08-25 SG SG2012007464A patent/SG178231A1/en unknown
- 2010-08-25 US US13/389,525 patent/US8796269B2/en active Active
- 2010-08-25 EA EA201270302A patent/EA021411B1/ru not_active IP Right Cessation
- 2010-08-25 DK DK10747619.4T patent/DK2470545T3/da active
- 2010-08-25 PL PL10747619T patent/PL2470545T3/pl unknown
- 2010-08-25 ES ES10747619.4T patent/ES2440938T3/es active Active
- 2010-08-25 AU AU2010288502A patent/AU2010288502B2/en active Active
- 2010-08-25 JP JP2012526048A patent/JP2013503134A/ja active Pending
- 2010-08-25 WO PCT/EP2010/062420 patent/WO2011023733A1/en not_active Ceased
- 2010-08-25 MX MX2012002369A patent/MX2012002369A/es active IP Right Grant
- 2010-08-25 CA CA2772168A patent/CA2772168C/en active Active
- 2010-08-25 EP EP10747619.4A patent/EP2470545B1/en active Active
-
2012
- 2012-02-02 ZA ZA2012/00812A patent/ZA201200812B/en unknown
- 2012-02-02 IL IL217922A patent/IL217922A/en active IP Right Grant
-
2015
- 2015-07-13 JP JP2015139845A patent/JP6404186B2/ja active Active
-
2017
- 2017-06-09 JP JP2017114602A patent/JP2017193564A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2012002369A (es) | 2012-03-29 |
| WO2011023733A1 (en) | 2011-03-03 |
| IL217922A (en) | 2016-06-30 |
| US20120157450A1 (en) | 2012-06-21 |
| AU2010288502A1 (en) | 2012-02-23 |
| JP2016000739A (ja) | 2016-01-07 |
| US8796269B2 (en) | 2014-08-05 |
| CN102639536B (zh) | 2015-03-18 |
| EP2470545A1 (en) | 2012-07-04 |
| IL217922A0 (en) | 2012-03-29 |
| JP2017193564A (ja) | 2017-10-26 |
| ZA201200812B (en) | 2013-03-27 |
| BR112012003435A2 (pt) | 2016-02-23 |
| EA201270302A1 (ru) | 2012-07-30 |
| CN102639536A (zh) | 2012-08-15 |
| ES2440938T3 (es) | 2014-01-31 |
| EP2470545B1 (en) | 2013-10-09 |
| CA2772168A1 (en) | 2011-03-03 |
| JP2013503134A (ja) | 2013-01-31 |
| EA021411B1 (ru) | 2015-06-30 |
| KR20120056258A (ko) | 2012-06-01 |
| CA2772168C (en) | 2019-01-08 |
| AU2010288502B2 (en) | 2013-12-12 |
| DK2470545T3 (da) | 2014-01-13 |
| PL2470545T3 (pl) | 2014-03-31 |
| SG178231A1 (en) | 2012-03-29 |
| JP6404186B2 (ja) | 2018-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN01292A (OSRAM) | ||
| MX2011011661A (es) | Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750. | |
| MX2011008864A (es) | Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales. | |
| PH12013500473A1 (en) | Triazine-oxadiazoles | |
| MY149731A (en) | Compounds | |
| PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
| MX2012013274A (es) | Novedosos derivados de la pirimidina. | |
| UA109010C2 (en) | Morpholino pyrividines and their use in therapy | |
| IN2012DN03182A (OSRAM) | ||
| MX2010002461A (es) | (carboxilalquilenfenil)feniloxamidas, metodo para su produccion y uso de las mismas como medicamento. | |
| MX2010002419A (es) | (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento. | |
| IN2014CN04530A (OSRAM) | ||
| MY187718A (en) | Pharmaceutical formulations | |
| MY160625A (en) | Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation | |
| IN2012DN02139A (OSRAM) | ||
| MX2013010898A (es) | Novedoso derivados de la pirimidina. | |
| MX2010002210A (es) | Derivados de catecolamina y profarmacos de los mismos. | |
| IN2015DN01119A (OSRAM) | ||
| MX2011011776A (es) | Nuevos profarmacos de triptolite. | |
| JO2682B1 (en) | Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof | |
| MY161749A (en) | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | |
| MX2013006670A (es) | Derivado de 2-carboxamida-4-piperazinil-benzofurano. | |
| MX2012007253A (es) | Derivados triciclicos y sus usos y composiciones farmaceuticas. | |
| MX2011008126A (es) | Compuestos de indol sustituidos como moduladores del receptor 1 de bradiquinina. | |
| IN2012DN02698A (OSRAM) |